K
Kesios Therapeutics
Novel therapeutics for multiple myeloma and other cancers
About Kesios Therapeutics
Kesios Therapeutics Limited was a UK-based biotechnology company focused on developing treatments for multiple myeloma and other cancers with significant unmet medical needs. The company was founded in 2012 as a spin-out from Imperial College London, based on the research of Professor Guido Franzoso from the Department of Medicine. Kesios operated from laboratories at the Imperial College Incubator in London.
The company's core strategy was to target the NF-κB signaling pathway, which, when abnormally activated, allows cancer cells to survive. Kesios developed drug candidates to disrupt a novel target within this pathway, the GADD45β/MKK7 complex, aiming to selectively kill cancer cells without harming normal cells. The lead drug candidate, KES-0001, was a tripeptide designed to restore apoptosis (programmed cell death) in myeloma cells and was advancing towards clinical studies for multiple myeloma.
The company assembled an experienced management team, notably appointing Dr. Paolo Paoletti, the former president of GSK Oncology, as Executive Chairman and later CEO in 2015. This leadership also included Jane Robertson as Chief Medical Officer and Peter Charlton as Chief Scientific Officer. The business model was centered on advancing its pipeline through clinical trials to validate its therapeutic approach. Kesios secured funding from a syndicate of major international investors. In October 2014, it received £1.9 million in a seed round from Imperial Innovations. This was followed by a significant Series A financing round in December 2015, raising £19 million (approximately $28.6 million) from investors including Imperial Innovations, SV Life Sciences, and Abingworth. This funding was intended to advance KES-0001 through Phase I/II clinical trials.
However, the company faced challenges in replicating the foundational pre-clinical results. An investor, Abingworth, later reported that Kesios could not replicate the pre-clinical assays of the inventor, leading to the suspension of further development work. According to PitchBook, the company is now out of business as of November 2016.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 59.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Oncology, Spinout, Biotech and Pharma, uk is8 life sciences, UKSU, UKSU2010, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Aug 2021 | $30M | $119M | Imperial Innovations · SV Life Sciences · Abingworth | — |
| DEBTDebt | Aug 2016 | $0 | — | SV Health Investors | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Kesios Therapeutics is 20 monthly website visits, down 86.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
BioCaptivaNovel liquid biopsy device for cancer diagnostics |
St Andrews, United Kingdom | Operational | 9 | $6.2M | $14M |
Myricx BioNovel antibody-drug conjugate payloads for cancer treatment |
London, United Kingdom | Acquired | |||
SpireaAdvanced antibody-drug conjugate technology for cancer therapeutics |
Harrogate, United Kingdom | Operational | |||
Leucid BioNext-generation CAR-T cell therapies for refractory cancers |
London, United Kingdom | Operational | |||
DxCoverDeveloping a spectroscopic liquid biopsy for rapid detection of cancer |
Glasgow, United Kingdom | Operational | |||
DJS AntibodiesAntibody therapeutics for chronic inflammatory and fibrotic diseases |
Oxford, United Kingdom | Acquired | |||
Argonaut TherapeuticsDeveloping epigenetic therapies targeting abnormal arginine methylation |
Oxford, United Kingdom | Acquired | |||
FemtogenixDNA-interactive payloads for antibody-drug conjugates |
St Albans, United Kingdom | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Kesios Therapeutics in the Cambourne ecosystem
The Kesios Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Imperial Innovations
Series A2 investors entered at this stage
Abingworth
SV Life Sciences
Series B and later1 investor entered at this stage
SV Health Investors
Other known investors2 additional known investors
College of Medicine and Integrated Health
Imperial College London
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Kesios Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Kesios Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










